PPAR agonists are a class of potentialantiplatelet drugs that are easily administered and have the ability to impactthis new physiology of platelet function.Even though PPAR agonists are primarilyprescribed for the treatment of metabolic disorders, some possess the secondarybenefit of inhibiting cardiovascular complications associated withhyperlipidemia and hyperglycemia. This evidence concerns the gene PPARA and Other metabolic disease.